Apresentação - Ciência 2016

Investigação Translacional em Medicina
Manuel Carrondo
Prof. Chem & Biochem Eng.,FCT/UNL
Vice President, iBET
Coordinator, iNOVA4Health
Ciência 2016
Centro de Congressos de Lisboa, 4 de Julho
Translational Research Medicine
Leads to new or improved
scientific
understanding
or
standards of care;
Patient
Oriented Research
Leads to better patient outcomes,
the implementation of best
practices and improved health
status in communities;
Basic Research
Population-Based
Research
Stimulates a robust scientific
understanding of human health
and disease.
Rubio, D.M., Schoenbaum, E.E. et al (2010) – “Defining Translational Research: Implications for
Training” Acad. Med., 85(3), 470-475
Ciência 2016 | iNOVA4Health
1
Translational Research Medicine
Two major Translational
Roadblocks/Bottlenecks:
NIH NCATS bridging the gap
by:
• Prevents basic research findings
from being tested in a clinical
setting;
• Developing: new approaches,
technologies, resources and
models:
• Prevents proven interventions from
becoming standard practice
• Demonstrating their usefulness;
• Disseminating the resulting data,
analysis and methodologies to the
broad scientific community
(Inst. Medic. Clinical Research roundtable)
Ciência 2016 | iNOVA4Health
2
BioPharma reorganization – Open-Source Model
Lilly’s FIPNet Model
Coping with the complexity and re-invigorating R&D
Kaitin, Clin Pharmacol Ther, 87:3, 356, 2010; Munos, Nature Rev Drug Discovery, 2010
Ciência 2016 | iNOVA4Health
3
Main Partners: Biopharmaceutical
Discovery
Mab’s
Bayer HealthCare, Köln & Wuppertal
Novartis Pharma, Basel
Proteomics
Bayer HealthCare, Berlin
Merck Healhcare, Darmstadt & Boston
Preclinical
Biologicals & ATMP’s
Apceth, München
Alloksys, Nunnik, NL
Bayer HealthCare, Wuppertal
Genethon, Paris
Merck Healthcare, Darmstadt
Novo Nordisk, Copenhagen
Redbiotech, Zurich
Sanofi Pasteur, Lyon
Pre-Clinical Models & Stem Cells
Development & Engineering
Abbvie, Chicago
Apceth, München
AstraZeneca, Göteburg
Cellartis, Takara Göteburg
Centocor, J&J, NJ
CEVEC, Köln
Merck Healthcare, Darmstadt
PBS, LA, California
Tecnimede, Portugal
BioReliance, Edinburgh
GlycoFi, New Hampshire
Leti, Madrid
Lonza, Slough & Visp
Merck Millipore, Boston & Darmstadt
Merck & Co., West Point, PA
GlaxoSmithKline, Sienna
PALL Life Sciences, Northborough, MA
Sartorius-Stedim, Göttingen
Ciência 2016 | iNOVA4Health
4
Basic Science, Technological Development and Precision
Medicine Driving HealthCare
Challenges
Solutions
Metabolism & Inflammation
Healthy Ageing
Rare Chronic Diseases
Novel Therapies
Mental Disorders
Biopharmaceuticals
Cancer
Personalized
medicine
Competences
Basic Research
Translational Research
Clinical Research
Ciência 2016 | iNOVA4Health
5
For more information visit: www.inova4health.com
Project name
PIs
Novel noninvasive markers of non-alcoholic fatty liver disease progression
and newly therapeutic approaches
Paula Macedo (CEDOC);
Ana Matias (iBET)
OrangeCTherapy: Chemotherapeutic effect of Citrus bioactive compounds
- evaluation for targeting human colorectal cancer stem cells
Teresa Serra (iBET);
Paula Chaves (IPOLFG)
Generation of genetically-modified hiPSC cell lines for the development of
a new transcriptional program sensor system for diagnoses and
therapeutics
Alisson Gontijo (CEDOC);
José Ramalho (CEDOC);
Patrícia Gomes-Alves (iBET)
Ovarian cancer a suitable model to define metabolic profile as a tool to
predict chemoresistance
Jacinta Serpa (IPOLFG/ CEDOC);
Vítor Espírito Santo (iBET);
Ana Félix (IPOLFG/ CEDOC)
CardioRegen: Integrative studies in cardiogenesis: from the embryo to
scalable multipronged generation of hESC-derived myocardial cells for
heart tissue repair
José Belo (CEDOC);
Paula Alves (iBET/ ITQB NOVA)
Molecular mechanisms of cell migration and invasion: developing a new
strategy to impair tumor progression
Duarte Barral (CEDOC); Cristina Casalou
(CEDOC); Jacinta Serpa (IPOLFG/CEDOC);
Ana Félix (IPOLFG/CEDOC, RG17)
Biomarkers for Autosomal Dominant Polycystic Kidney Disease (ADPKD
biomarkers)
Mónica Rosa (CEDOC); Susana Lopes
(CEDOC); Fernando Nolasco (CEDOC)
The role of cholesteryl hemiesters in the etiology, development and
instability of atheromata
Otília Vieira (CEDOC); José Alves
(CEDOC); Winchil Vaz (CEDOC); Miguel
Viana Baptista (CEDOC)
Ciência 2016 | iNOVA4Health
6
For more information visit: www.inova4health.com
Project name
PIs
Development of a non-invasive method to measure blood glucose through
the skin without need of calibration
Abel Oliva (ITQB NOVA);
Paula Macedo (CEDOC)
The importance of haptoglobin/hemopexin axis in the pathogenesis of
Axial Spondyloarthritis
Raffaella Gozzelino (CEDOC);
Fernando Pimentel-Santos (CEDOC);
Jaime Branco (CEDOC)
T2C – Development of a novel delivery system (DS) to Target metastatic
colorectal Cancer (mCRC)
Cristina Albuquerque (IPOLFG);
Catarina Duarte (iBET/ ITQB NOVA)
Characterization of anti-HDL (aHDL) antibodies: identification of their
biologic activity and clinical relevance
José Alves (CEDOC);
Maria Arménia Carrondo (ITQB NOVA)
Remote ischemic per-conditioning in acute stroke – clinical trial for
improving outcome and disclosing novel circulating biomarkers
Helena Vieira (CEDOC);
Miguel Viana Baptista (CEDOC)
SynDia: Synucleins – the link between Parkinson and Diabetic
Retinopathy?
Sandra Tenreiro (CEDOC);
Gabriela Silva (CEDOC);
Cláudia Santos (iBET/ ITQB NOVA)
Rewired T Cells: New therapeutic opportunities for Rheumatoid Arthritis
Helena Soares (CEDOC);
Jaime Branco (CEDOC)
Development of Novel Cancer Therapeutics for Breast Cancer targeting
Notch1 ligands Delta-like-1 and Jagged2
Ana Barbas (iBET);
Sofia Braga (CEDOC)
Ciência 2016 | iNOVA4Health
7
For more information visit: www.inova4health.com
Project name
PIs
Molecular profiling and novel targeted therapies in thyroid and colorectal
cancers
Branca Cavaco (IPOLFG);
Teresa Serra (iBET)
Depicting Barrett’s esophagus biopathogenesis and its malignant
progression in three-dimensional in vitro models
Paula Chaves (IPOLFG);
Manuel Carrondo (iBET)
Colorectal Carcinogenesis Pathways - Establishing a link between
carcinogenesis & therapeutic response
Isadora Rosa (IPOLFG);
Catarina Brito (iBET/ ITQB NOVA)
(per)Sulfidomics: benchmarking mechanisms underlying drug toxicity and
drug resistance in precision medicine
João Vicente (ITQB NOVA);
Jacinta Serpa (IPOLFG/ CEDOC);
Sofia Pereira (CEDOC)
MioSpA: the role of the muscle in Spondyloarthritis, a new paradigm
Fernando Pimentel-Santos (CEDOC);
Júlia Costa (ITQB NOVA)
Searching for positive markers in triple negative breast cancer
Sofia Braga (CEDOC);
António Jacinto (CEDOC);
Sofia Rebelo (iBET)
The effect of dual HER2 blockade on anti-tumor immune cells
Inês Pires Silva (IPOLFG);
Catarina Brito (iBET/ ITQB NOVA)
Ciência 2016 | iNOVA4Health
8
Thank you
Manuel Carrondo
[email protected]
The iNOVA4Health Research Unit (UID/Multi/04462/2013), is cofunded by Fundação para a Ciência e Tecnologia /
Ministério da Ciência e do Ensino Superior, through national funds and by FEDER under the PT2020 Partnership
Agreement.